Skip to main content

Table 2 Predictors of IPF disease progression at week 52

From: Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

Univariate analysis Multivariate analysis
Parameter Odds ratio 90% CI p-value Parameter Odds ratio 95% CI p-value
(A) Pirfenidone group        
Gender; male vs. female 0.529 0.260, 1.077 0.1407 Gender; male vs. female    
Age 0.968 0.927, 1.011 0.2223 Age    
BMI 0.822 0.734, 0.921 0.0047 BMI 0.849 0.723, 0.998 0.0469
Smoking; current and former vs. never 0.444 0.224, 0.880 0.0510 Smoking; current and former vs. never 0.831 0.305, 2.266 0.7172
Dyspnea scale (modified by Fletcher) 1.359 0.884, 2.089 0.2413 Dyspnea scale (modified by Fletcher)    
PaO2 1.016 0.984, 1.050 0.4188 PaO2    
AaDO2 0.968 0.940, 0.998 0.0806 AaDO2 0.969 0.932, 1.007 0.1069
Lowest SpO2 during a 6MET 1.011 0.888, 1.151 0.8881 Lowest SpO2 during a 6MET    
%VC 0.939 0.918, 0.960  < 0.0001 %VC 0.943 0.916, 0.971  < 0.0001
%DLCO 1.011 0.995, 1.029 0.2653 %DLCO    
Serum SP-D 1.004 1.002, 1.006 0.0059 Serum SP-D 1.003 1.000, 1.006 0.0278
Serum SP-A 0.997 0.989, 1.004 0.4486 Serum SP-A    
Serum KL-6 1.000 0.999, 1.000 0.2321 Serum KL-6    
(B) Placebo group        
Gender; male vs. female 0.700 0.317, 1.546 0.4589 Gender; male vs. female    
Age 0.995 0.950, 1.042 0.8616 Age    
BMI 0.791 0.690, 0.908 0.0053 BMI 0.833 0.704, 0.985 0.0323
Smoking; current and former vs. never 0.509 0.222, 1.166 0.1803 Smoking; current and former vs. never    
Dyspnea scale (modified by Fletcher) 1.187 0.696, 2.025 0.5979 Dyspnea scale (modified by Fletcher)    
PaO2 0.973 0.937, 1.011 0.2349 PaO2    
AaDO2 1.005 0.971, 1.041 0.8057 AaDO2    
Lowest SpO2 during a 6MET 0.839 0.708, 0.994 0.0889 Lowest SpO2 during a 6MET 0.908 0.723, 1.141 0.4084
%VC 0.949 0.925, 0.973 0.0006 %VC 0.957 0.927, 0.987 0.0049
%DLCO 0.981 0.962, 1.001 0.1139 %DLCO    
Serum SP-D 1.001 0.999, 1.002 0.6032 Serum SP-D    
Serum SP-A 1.001 0.996, 1.007 0.7249 Serum SP-A    
Serum KL-6 1.000 1.000, 1.000 0.9441 Serum KL-6    
  1. The disease progression was defined by a > 10% relative decline in vital capacity from baseline and/or death. Logistic regression analysis
  2. IPF idiopathic pulmonary fibrosis, CI confidence interval, BMI body mass index, PaO2 partial pressure of oxygen in arterial blood, AaDO2 alveolar–arterial oxygen difference, SpO2 peripheral capillary oxygen saturation, 6MET 6-min steady-state exercise test, VC vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, SP surfactant protein, KL Krebs von den Lungen